炎症性肠病患者治疗相关并发症的预测、预防与管理
本文综述了炎症性肠病(IBD)患者治疗相关并发症的预测、预防和管理策略,强调遵守禁忌症可降低特定药物并发症风险。主要涉及感染、淋巴瘤和皮肤癌等并发症,并提出了疫苗接种、潜伏结核筛查和特定药物使用限制等预防措施。
要点
- 免疫抑制治疗前应更新疫苗接种,避免活疫苗,并筛查潜伏结核。
- 硫嘌呤增加严重病毒感染风险,TNF拮抗剂增加所有类型严重感染风险。
- 限制硫嘌呤用于EBV血清阴性患者(尤其年轻男性)和老年男性以降低淋巴瘤风险。
核心结论
- 遵守禁忌症可降低IBD特定药物并发症风险,需重视感染预防和癌症监测。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- IBD患者常发生严重感染,源于疾病本身或治疗。
- 硫嘌呤促进严重病毒感染,TNF拮抗剂促进所有类型严重和机会性感染。
- 托法替尼以剂量和年龄依赖方式促进带状疱疹感染。
- 硫嘌呤诱导的淋巴瘤风险可通过限制EBV血清阴性患者(尤其年轻男性)和老年男性使用来降低。
- 抗TNF单药治疗相关淋巴瘤风险仍不明确。
关键数值与推荐
- 诊断时根据IBD指南更新疫苗接种日历,接受免疫抑制药物的患者推迟活疫苗。
- 开始免疫抑制治疗前检测机会性感染并接种肺炎球菌疫苗。
- 开始抗TNF治疗和其他新IBD药物前必须检测和治疗潜伏结核。
- 考虑在开始免疫抑制治疗前给予带状疱疹活疫苗,或治疗期间任何时间点使用重组疫苗(当可用时)。
- 对有既往癌症且复发风险高的患者,尝试暂停免疫抑制治疗(除严重疾病且无治疗替代者),优先使用致癌效应最低的IBD药物。
临床怎么用
- 临床应遵循指南更新疫苗接种、筛查潜伏结核和机会性感染。
- 根据患者特征(如EBV血清状态、年龄)个体化选择药物以降低淋巴瘤风险。
- 对有癌症史患者优先选择低致癌风险药物并考虑暂停免疫抑制。
- 从诊断开始推荐防晒和皮肤监测。
局限性
- 新近IBD药物的致癌效应缺乏可靠数据。
- 抗TNF单药治疗相关淋巴瘤风险仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk of complications from specific classes of drugs for inflammatory bowel diseases (IBDs) can be kept low by respecting contraindications. Patients with IBD frequently develop serious infections resulting from the disease itself or its treatment. At the time of diagnosis, patients' vaccination calendars should be updated according to IBD guidelines-live vaccines should be postponed for patients receiving immunosuppressive drugs. Opportunistic infections should be detected and the vaccine against pneumococcus should be given before patients begin immunosuppressive therapy. Thiopurines promote serious viral infections in particular, whereas tumor necrosis factor (TNF) antagonists promote all types of serious and opportunistic infections. Severe forms of varicella can be prevented by vaccinating seronegative patients against varicella zoster virus. Detection and treatment of latent tuberculosis is mandatory before starting anti-TNF therapy and other new IBD drugs. Tofacitinib promotes herpes zoster infection in a dose- and age-dependent manner. Physicians should consider giving patients live vaccines against herpes zoster before they begin immunosuppressive therapy or a recombinant vaccine, when available, at any time point during treatment. The risk of thiopurine-induced lymphomas can be lowered by limiting the use of thiopurines in patients who are seronegative for Epstein-Barr virus (especially young men) and in older men. The risk of lymphoma related to monotherapy with anti-TNF agents is still unclear. There are no robust data on the carcinogenic effects of recently developed IBD drugs. For patients with previous cancer at substantial risk of recurrence, physicians should try to implement a pause in the use of immunosuppressive therapy (except in patients with severe disease and no therapeutic alternative) and prioritize use of IBD drugs with the lowest carcinogenic effects. Finally, sun protection and skin surveillance from the time of diagnosis are recommended.
引用
- Beaugerie L, Rahier JF, Kirchgesner J, et al. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020. PMID: 32059920. doi:10.1016/j.cgh.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。